19 Nov 2001, 14:29 UTC
Morning Market View for November 19, 2001
- From
- Schwab Alerts schwabalerts.marketupdates@schwab.com
- Date
- Mon, 19 Nov 2001 06:29:23 -0800 (PST)
Charles Schwab & Co., Inc.
Email Alert
Morning Market View(TM)
for Monday, November 19, 2001
as of 9:30AM EST
Information provided by Schwab Center for Investment Research
MARKETS TO START WEEK ON A POSITIVE NOTE
Equities were poised to continue the uptrend from overseas at
the open on mostly upbeat homebuilding data. October housing
starts reflected a softening but still robust market for new
home building, while the more forward-looking building permits
pointed to a potentially deteriorating situation. In equities
news, home-improvement retailer Lowe's Companies (LOW,40) posted
strong 3Q results and gave optimistic guidance, while oil giants
Phillips Petroleum (P,52,f2) and Conono Inc. (COC,24,f2)
announced a strategic merger.
Phillips Petroleum has agreed to purchase rival Conoco Inc. for
$15.4 billion, creating the third-largest U.S. oil company in a
move to enhance competitive positioning. Conoco shareholders
will receive 0.4677 shares of the combined company,
ConocoPhillips, for each of their original shares, valuing the
shares at $24.30, roughly equal to Friday's closing price.
Additionally, Phillips' CEO said the company will eliminate jobs
following the merger in an effort to reign in costs and cut
duplicate positions. The companies hope to close the deal by the
second half of 2002.
Lowe's Companies posted a 24% rise in fiscal 3Q net income to
$0.32 per share, $0.01 ahead of the First Call $0.31 per share
consensus forecast. Sales rose 21% to $5.45 billion, with
same-store sales rising 4%. The company's CEO noted strength in
all product categories across every geographic region and said
that consumer traffic accelerated during the quarter. Lowe's
expects fiscal 2002 profits of $1.24-$1.25 per share, ahead of
the Street's $1.23 mean estimate.
Shares of Andrx Group (ADRX,63,f1) were higher in premarket
activity after the generic drug maker reported Friday that the
FDA had granted it permission to market a generic form of
AstraZeneca PLC's (AZN,46,f2) Prilosec ulcer medication, which
generated more than $6 billion in global sales last year.
Although AstraZeneca's primary U.S. patent on the drug expired
on Oct. 5, the London-based pharmaceutical manufacturer claims
that generic versions of the drug would violate several related
patents, which, if upheld, would prolong U.S. exclusivity rights
for several years.
----------------------------------------------------------------
TREASURY AND ECONOMIC SUMMARY
Treasuries rose following the release of this morning's housing
starts data. Total starts for October fell 1.3% to a 1.552
million annual rate from September's revised 1.572 million pace.
Analysts were expecting a 4.7% decline to an annual rate of
1.500 million starts. The weakness was most noticeable in the
West. Despite the unexpected resiliency in the housing market,
buoyed by historically low interest rates, the more
forward-looking building permits fell 3.6% in October on the
heels of a revised 2.7% decline the prior month. Permits were
previously reported as having dropped 3.0% in September.
----------------------------------------------------------------
WORLD MARKETS
Despite a Bundesbank report that German economic growth was
sequentially flat in 3Q and may be weaker in 4Q, European
bourses climbed higher on renewed optimism that lower interest
rates and falling crude prices will eventually stimulate
economic growth in 2002. The Bloomberg 500 index was up 1.3% as
of 8:56 a.m. EST, led by computer-related and telecom stocks.
The euro was lower against the dollar after hawkish European
Central Bank officials commented that current euro-zone interest
rates are appropriate.
Asian markets were also higher, with Japan's Nikkei-225 index
closing up 0.74%, in spite of the Bank of Japan's dour
assessment of the economy, including concerns about the effects
of declining exports and output on consumer sentiment and
spending. The yen was lower against the dollar following the
Bank of Japan's economic downgrade. Nevertheless, enthusiasm
about an improving outlook in the U.S., as well as a softer yen,
carried export stocks, including Toyota (TM,50,f2) and Sony
Corp. (SNE,46) higher. Crude oil trailed lower again amid fresh
concerns that Russia will offer nothing more in the way of
concessions than a meager, symbolic production cut.
----------------------------------------------------------------
FUTURES WATCH
In the December Globex futures contract as of 8:56 a.m. EST, the
S&P 500 index was 7 points higher while the Nasdaq 100 index was
up 19 points. The December DJIA futures contract was up 55
points (58 points above fair value) and the December crude oil
futures traded on the NYMEX were down $0.79 at $17.24/barrel.
William Johnson, Market Analyst
================================================================
LOGIN to access your account:
https://investing.schwab.com/trading/start
----------------------------------------------------------------
To unsubscribe or modify your Email Alert customization options,
log in using the link below or copy and paste it into your
browser's address window:
https://investing.schwab.com/trading/start?SANC=EAMyAlerts
----------------------------------------------------------------
Notice: All email sent to or from the Charles Schwab corporate
email system may be retained, monitored and/or reviewed
by Schwab personnel. (0801-11478)
Charles Schwab & Co., Inc. ("Schwab") is a member of the NYSE,
other major U.S. Securities Exchanges, and SIPC. Schwab is a
specialist in various securities on the Pacific, Boston and
Cincinnati Stock Exchanges and is subsidiary of The Charles
Schwab Corporation, which is listed on the NYSE and trades
under the symbol "SCH". Schwab Capital Markets L.P. is a member
of the NASD and SIPC.
Schwab Capital Markets L.P. is also a subsidiary of The Charles
Schwab Corporation and is a market maker in approximately
4,900 securities.
Schwab Center for Investment Research ("SCIR") is part of
Charles Schwab & Co., Inc. The information contained herein is
obtained from sources believed to be reliable, but its accuracy
or completeness is not guaranteed. This report is for
informational purposes only and is not a solicitation, or a
recommendation that any particular investor should purchase or
sell any particular security. Schwab does not assess the
suitability or the potential value of any particular
investment. All expressions of opinions are subject to change
without notice. The Charles Schwab Corporation, Schwab, Schwab
Capital Markets L.P. and its officers, directors, employees,
consultants and/or members of their families may have a position
in, and may from time to time, purchase or sell any of the
mentioned or related securities including derivatives in such
securities. At any given time, Schwab specialists, or Schwab
Capital Markets L.P. market makers, may have an inventory
position, either "long" or "short" in any security mentioned in
this report as a result of their specialist/market making
functions, respectively. Additionally, Schwab or Schwab
Capital Markets L.P. may be on the opposite side of orders
executed on the floor of the Pacific, Boston and/or Cincinnati
Stock Exchanges or over-the-counter market respectively, as
well. Schwab (or persons related thereto) or consultants may
perform or solicit investment banking or other business from
any company mentioned in this report.
(C)2001 Charles Schwab & Co., Inc.
1) Schwab Capital Markets L.P. makes a market in this security.
2) Schwab is a specialist in this security.
3) Schwab has managed or co-managed a public offering in this
security within the last three years.
4) An employee of Schwab is a Director of this company.
5) An analyst covering this stock has an investment position.
Commercial use or redistribution in any form, print or
electronic, is prohibited.
Distribution by Quris, Inc.